Topic:

Partnering

Latest Headlines

Latest Headlines

Navidea joins forces with Norgine to market cancer imaging Dx in EU

Navidea Biopharmaceuticals is teaming up with European specialty pharma company Norgine to commercialize its Lymphoseek cancer diagnostic aid in Europe, looking to make a market splash as it drives international growth.

Hutchison China MediTech eyes first modern drug approval in China next year with Eli Lilly candidate

Hutchison China MediTech, based in Hong Kong, expects to file for its first drug approval next year for what it said would be the first modern drug developed in China since artemisinin was developed in the 1970s to treat malaria.

Denovo Biopharma eyes China trial of licensed Eli Lilly neuroscience drug

Denovo Biopharma will conduct clinical trials in China for its exclusively licensed pomaglumetad methionil, a late-stage neuroscience drug licensed from Eli Lilly.

Hanmi licenses poziotinib to U.S-based Spectrum outside of China, South Korea

Hanmi Pharmaceutical has licensed its poziotinib for treating several types of cancer to U.S.-based Spectrum Pharmaceuticals.

ASLAN's Carl Firth on Taiwan's biotech momentum and valuations

Taiwan's momentum as a biotech clinical trials hub in Asia remains strong, but valuations for listed biotech firms may not yet reflect a wide smart money view on eventual commercial prospects, according to Carl Firth, the CEO of Aslan Pharmaceuticals.

J&J opens Silicon Valley incubator in collaboration with PerkinElmer

Laboratory equipment and services company PerkinElmer announced that it will provide Johnson & Johnson's new San Francisco life science incubator with on-site staff, training and scientific application support.

Mayo Clinic, Gentag partner to develop movement sensor patches

The Mayo Clinic and Gentag are partnering to develop next-generation, wireless, disposable patch sensors to enable researchers to track patient movements in order to better address conditions such as diabetes and obesity.

Startup Alkahest inks a $50M deal for anti-aging R&D

Alkahest, a member of Johnson & Johnson's just-launched biotech incubator, signed a $50 million agreement with Spanish giant Grifols to hit the gas on its novel approach to treating neurodegeneration.

UPDATED: Bristol-Myers forges a billion-dollar cancer vaccine deal with Bavarian Nordic

Bristol-Myers Squibb has swooped in with $60 million upfront to gain an option on Bavarian Nordic's Phase III therapeutic prostate cancer vaccine Prostvac, ready to shell out an additional $915 million-plus in milestones if it takes the next step to license and ultimately commercialize the therapy.

Alexion bets up to $265M on Blueprint's precision medicine platform

Rare disease magnate Alexion is aligning itself with biotech Blueprint Medicines, borrowing the company's development technology to spotlight new treatments for genetic disorders.